OR WAIT 15 SECS
© 2020 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2020 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Regulatory, analytical, and process concerns must be considered.
Novel coronavirus can pose threats to bioprocessing.
October 23, 2020
Edge-AI technology will enable Industry 4.0 automation in pharmaceutical manufacturing.
October 21, 2020
Automation, digitalization, and supply-chain strategies help mitigate vulnerabilities in both autologous and allogeneic cell therapy manufacturing.
Automation and tools for remote monitoring are finding increased use as pharmaceutical manufacturing adapts to pandemic restrictions.
October 20, 2020
The company’s new closed cell therapy processing system enables scalable, cost-effective development and manufacturing of cell therapies.
October 16, 2020
The new VirusExpress lentiviral production platform increases dose yields and reduces process development time for cell and gene therapies.
The new facility at the company’s San Diego, CA, site will be for late phase and commercial CGMP manufacturing.
October 15, 2020
Ongoing and emerging cyber-risks to legacy operational technology systems in bio/pharmaceutical manufacturing must be addressed.
FDA’s final CMC guidance sets expectations for manufacturing and quality for human gene therapy INDs. This article reviews existing analytical applications, focusing on viral vector characterization of impurities.
Cytiva will provide the first FlexFactory to be used in the manufacture of pDNA to Akron Bio.
October 13, 2020
Virtual Touring allows companies to inspect and visit vendor and contract partner sites remotely during the COVID-19 pandemic.